OMER / Omeros Corporation - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 OMEROS CORPORATIO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Omeros Corporation Reports Second Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 14, 2025 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: ● Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per sha

Securities Purchase Agreement, dated as of July 24, 2025, by and between the Company and the investor named therein.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of July 24, 2025, by and among Omeros Corporation, a Washington corporation (the “Company”), and each of the entities listed on the signature page hereto (each, an “Investor” and together, the “Investors”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuan

5,365,853 Shares of Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(3)  Registration No. 333-268259 PROSPECTUS SUPPLEMENT (To Prospectus dated November 17, 2022) 5,365,853 Shares of Common Stock We are offering 5,365,853 shares of our common stock, par value $0.01 per share, directly to an institutional investor pursuant to this prospectus supplement and the accompanying prospectus, at a purchase price equal to $4.1

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Exhibit 99.1 Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering SEATTLE, WA – July 25, 2025 – Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering. Under the te

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 OMEROS CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Placement Agent Agreement, dated as of July 24, 2025, by and between the Company and D. Boral Capital LLC.

Exhibit 10.2 OMEROS CORPORATION 5,365,853 Shares of Common Stock PLACEMENT AGENT AGREEMENT July 24, 2025 D. Boral Capital LLC 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: Subject to the terms and conditions herein (this “Agreement”) Omeros Corporation, a Washington corporation (the “Company”), hereby agrees to sell up to an aggregate of 5,365,853 shares (the “Share

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 OMEROS CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 OMEROS CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

Second Supplemental Indenture, dated as of May 14, 2025, between the Company and Computershare Trust Company, National Association, as trustee.

Exhibit 4.2 OMEROS CORPORATION and COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of May 14, 2025 9.50% Convertible Senior Notes due 2029 CROSS REFERENCE TABLE* Trust Indenture Act Indenture Section Section 310 (a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311 (a) N/A (b) N/A (c) N/A 312 (a) 2.08 (b) N/A (c) N/A 313 (a)

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Second Supplemental Indenture, dated as of May 14, 2025, between the Company and Computershare Trust Company, National Association, as trustee.

Exhibit 4.2 OMEROS CORPORATION and COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of May 14, 2025 9.50% Convertible Senior Notes due 2029 CROSS REFERENCE TABLE* Trust Indenture Act Indenture Section Section 310 (a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311 (a) N/A (b) N/A (c) N/A 312 (a) 2.08 (b) N/A (c) N/A 313 (a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Omeros Corporation Reports First Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports First Quarter 2025 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – May 15, 2025 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: ● Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, c

Form of Exchange Agreement, dated as of May 12, 2025, among the Company and the investors named therein.

Exhibit 10.1 Omeros Corporation Form of Exchange Agreement May 12, 2025 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 3 Section 3. The Exchange 3 (a) Generally 3 (b) The Closing 3 Section 4. Representations, Warranties and Covenants of the Company 6 (a) Due Formation, Valid Existence and Good Standing; Power to Perform Obligations 6 (b) Listing of Common Stock 6

Form of Note Conversion Agreement, dated as of May 12, 2025, among the Company and the holders named therein.*

Exhibit 10.2 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FORM OF NOTE CONVERSION AGREEMENT May 12, 2025 The investor party hereto (the “Undersigned”), for itself and on behalf of the beneficial owners listed o

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes due 2026

Exhibit 99.2 Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes due 2026 SEATTLE, WA – May 12, 2025 – Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company’s 5.25% Convertible Senior Notes du

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Exhibit 99.1 FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date SEATTLE, WA – May 6, 2025 – Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Seventeenth Amendment to Lease dated December 18, 2024 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.25 SEVENTEENTH AMENDMENT TO LEASE THIS SEVENTEENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 18th day of December, 2024 (the “Seventeenth Amendment Execution Date”) and is effective, retroactively, as of October 1, 2024 (the “Effective Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Wa

Combined Development and Commercial Supply Agreement, effective as of May 16, 2018, between Omeros Corporation and Vetter Pharma international GmbH

Exhibit 10.30 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. —CONFIDENTIAL— THIS COMBINED DEVELOPMENT AND COMMERCIAL SUPPLY AGREEMENT, made effective as of May 16, 2018 (this “Agreement”), by and between Omeros Corporation, a company duly organized and existing under the laws

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – March 31, 2025 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include: ● Net loss for the fourth quarter of 2024 was $31.4

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

Omeros Corporation Insider Trading Policy

Exhibit 19.1 OMEROS CORPORATION INSIDER TRADING POLICY Adopted June 26, 2023 TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 1 Compliance Officers 2 Reporting violations 2 Personal responsibility 2 PERSONS AND TRANSACTIONS COVERED BY THIS POLICY 3 Persons cov

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA – Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, ove

Exhibit 99.1 Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA – Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – ● Results of statistical analyses of survival in narsoplimab-treated expanded access program (EAP) TA-TMA p

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint – Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA –

Exhibit 99.1 Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint – Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – ● Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating: o Nar

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Exhibit 99.1 Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA ● Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treated with narsoplimab in an external control stem cell transp

Omeros Corporation Reports Third Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – November 13, 2024 – Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2024, which include: ● Net loss for the third quarter of 2024 was $32.2 million, or $0.56 per

Sixteenth Amendment to Lease dated July 8, 2024 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.1 SIXTEENTH AMENDMENT TO LEASE THIS SIXTEENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 8th day of July, 2024 (the “Sixteenth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant are parties to t

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

ear Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Fifteenth Amendment to Lease dated November 1, 2022 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.3 FIFTEENTH AMENDMENT TO LEASE THIS FIFTEENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 1st day of November, 2022 (the “Fifteenth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”). RECITALS A. WHEREAS, Landlord and Tenant are parties

Omeros Corporation Reports Second Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – August 7, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders incl

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Pledge and Security Agreement, dated as of June 3, 2024, between Omeros Corporation, nura inc. and Wilmington Savings Fund Society, FSB, as Collateral Agent

Exhibit 10.2 PLEDGE AND SECURITY AGREEMENT dated as of June 3, 2024 between EACH OF THE GRANTORS PARTY HERETO and WILMINGTON SAVINGS FUND SOCIETY, FSB, as Collateral Agent TABLE OF CONTENTS PAGE SECTION 1. DEFINITIONS 1 1.1 General Definitions 1 1.2 Definitions; Interpretation 9 SECTION 2. GRANT OF SECURITY 9 2.1 Grant of Security 9 2.2 Certain Limited Exclusions 10 SECTION 3. SECURITY FOR OBLIGAT

Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028

Exhibit 99.1 Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 ● $118.1 million, or 55%, of outstanding convertible notes due in 2026 repurchased at approximately 75% of notional value, resulting in $51 million in total debt extinguishment ● Repurchase funded from new $67 million secu

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Credit and Guaranty Agreement, dated as of June 3, 2024, among Omeros Corporation, certain subsidiaries of Omeros Corporation, as guarantors, various Lenders and Wilmington Savings Fund Society, FSB, as Administrative Agent and Collateral Agent

Exhibit 10.1 CREDIT AND GUARANTY AGREEMENT dated as of June 3, 2024 among OMEROS CORPORATION, as Company, and CERTAIN SUBSIDIARIES OF COMPANY, as Guarantors, VARIOUS LENDERS, WILMINGTON SAVINGS FUND SOCIETY, FSB, as Administrative Agent and Collateral Agent $92,077,469.33 Senior Secured Credit Facilities [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS

Omeros Corporation Reports First Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports First Quarter 2024 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – May 15, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders includi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Amendment No. 1 to License Agreement with an effective date of January 5, 2011 between Omeros Corporation and Daiichi Sankyo Co., Ltd.

Exhibit 10.24 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment No. 1 to LICENSE AGREEMENT This Amendment No. 1 to License Agreement (this “Amendment No. 1”) is made effective the 5th day of January 2011 (the “Effective Date”) between Daiichi Sankyo Company, Limited, a

Amendment No. 2 to License Agreement with an effective date of January 25, 2013 between Omeros Corporation and Daiichi Sankyo Co., Ltd.

Exhibit 10.25 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. Amendment No. 2 to LICENSE AGREEMENT This Amendment No. 2 to License Agreement (this “Amendment No. 2”) is made effective the 25 day of January 2013 (the “Effective Date”) between Daiichi Sankyo Company, Limited, a J

Omeros Corporation Compensation Clawback Policy

Exhibit 97.1 OMEROS CORPORATION COMPENSATION CLAWBACK POLICY PURPOSE The Board of Directors (the “Board”) of Omeros Corporation (the “Company”) has adopted this compensation clawback policy (the “Policy”), which provides for the recovery of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Section 10D of the Securities Exchange Act of 19

Amended and Restated Royalty Purchase Agreement between Omeros Corporation and DRI Healthcare Acquisitions LP dated February 1, 2024

Exhibit 10.30 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED ROYALTY PURCHASE AGREEMENT BETWEEN OMEROS CORPORATION AND DRI HEALTHCARE ACQUISITIONS LP Dated as of February 1, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS; INTERPRETATION Section 1.1. Def

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

License Agreement between Omeros Corporation and Daiichi Sankyo Co., Ltd. (successor-in-interest to Asubio Pharma Co., Ltd.) dated March 3, 2010

Exhibit 10.23 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENT between ASUBIO PHARMA CO., LTD. and OMEROS CORPORATION This license agreement (this “Agreement”) is made effective the 3rd day of March 2010 (the “Effective Date”) between Asubio Pharma Co., Ltd., a

Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results – Conference Call Today at 4:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results – Conference Call Today at 4:30 p.m. ET SEATTLE, WA – April 1, 2024 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic di

OMER / Omeros Corporation / Demopulos Gregory A MD - SCHEDULE 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 14)* OMEROS CORPORATION (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143 102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

OMER / Omeros Corporation / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Omeros Corp Title of Class of Securities: Common Stock CUSIP Number: 682143102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(

8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2024 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Omeros Corporation Reports Third Quarter 2023 Financial Results – Conference Call Today at 1:30 p.m. ET

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2023 Financial Results – Conference Call Today at 1:30 p.m. ET SEATTLE, WA – November 9, 2023 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy

Exhibit 99.1 Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy ● The ARTEMIS-IGAN trial did not reach statistical significance on the primary endpoint of reduction in proteinuria from baseline compared to placebo ● Proteinuria reduction in the placebo group was substantially greater than reported in other IgA nephropathy clinical

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

As filed with the Securities and Exchange Commission on August 9, 2023

As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) OMEROS CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit (3) Maximum Aggregate Offering Price (3) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 OMEROS CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Omeros Corporation Reports Second Quarter 2023 Financial Results – Conference Call Today at 8:30 a.m. ET –

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2023 Financial Results – Conference Call Today at 8:30 a.m. ET – SEATTLE, WA – August 9, 2023 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 OMEROS CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 23, 2023)

‌Exhibit 10.1 OMEROS CORPORATION 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 23, 2023) 1.Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility; · to provide additional incentive to Employees, Directors and Consultants; and · to promote the success of the Compan

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 OMEROS CORPORATION (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Omeros Corporation Reports First Quarter 2023 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports First Quarter 2023 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – May 9, 2023 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders includ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 OMEROS CORPORATION (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission

Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – March 13, 2023 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Omeros Corporation Non-Employee Director Compensation Policy

Exhibit 10.11 OMEROS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Omeros Corporation (the “Company”) believes that the granting of equity and cash compensation to its Directors represents a powerful tool to attract, retain and reward Directors who are not Employees of the Company (“Outside Directors”) and to align the interests of our Outside Directors with those of our shareholders. This

Technology License Agreement, effective August 28, 2020 between Omeros Corporation and Xencor, Inc.

Exhibit 10.1 [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TECHNOLOGY LICENSE AGREEMENT This TECHNOLOGY LICENSE AGREEMENT (this “Agreement”), effective as of August 28, 2020 (the “Effective Date”), is made by and between Omeros Corporation, a Delaware corporation (“Omeros”),

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

OMER / Omeros Corporation / Demopulos Gregory A MD Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 13)* OMEROS CORPORATION (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143 102 (CUSIP Number) December 31 , 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

OMER / Omeros Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01574-omeroscorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Omeros Corp. Title of Class of Securities: Common Stock CUSIP Number: 682143102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical – OMIDRIA®-Related Payment Expected to Provide Operating Capital into at Least 2025 –

Exhibit 99.l Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical – OMIDRIA®-Related Payment Expected to Provide Operating Capital into at Least 2025 – SEATTLE, WA – February 6, 2023 – Omeros Corporation (Nasdaq: OMER) today announced that Rayner Surgical, Inc. (“Rayner”) has paid the $200 million milestone payment due to Omeros under the Asset Purchase Agreement, dated

Common Stock Preferred Stock Debt Securities Depositary Shares Warrants Subscription Rights Units

TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3) ?Registration No. 333-268269? PROSPECTUS $300,000,000 By this prospectus, Omeros Corporation may from time to time offer and sell: Common Stock Preferred Stock Debt Securities Depositary Shares Warrants Subscription Rights Units ? From time to time, we may offer and sell up to $300,000,000 of the securities described in this prospectus separately

$150,000,000 Common Stock

424B5 1 tm2229812-4424b5.htm 424B5 TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-268269 PROSPECTUS SUPPLEMENT (To Prospectus dated November 17, 2022) $150,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “sales agreement”) with Cantor Fitzgerald & Co. (“Cantor”) relating to shares of our common stock offered by this prospectu

OMEROS CORPORATION 201 Elliott Avenue West Seattle, Washington 98119

OMEROS CORPORATION 201 Elliott Avenue West Seattle, Washington 98119 November 16, 2022 VIA EDGAR U.

LETTER

United States securities and exchange commission logo November 15, 2022 Peter Cancelmo General Counsel and Secretary OMEROS CORP 201 Elliott Avenue West Seattle, WA 98119 Re: OMEROS CORP Registration Statement on Form S-3 Filed November 9, 2022 File No.

As filed with the Securities and Exchange Commission on November 9, 2022

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 9, 2022 Registration No.

Omeros Corporation Reports Third Quarter 2022 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2022 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – November 9, 2022 – Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 OMEROS CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939

EXHIBIT 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) [] Computershare Trust Company, National Association (Exact name of trustee as specified in its charter)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Omeros Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration

Royalty Purchase Agreement dated September 30, 2022 between Omeros Corporation and DRI Healthcare Acquisitions LP

? Exhibit 10.1 ? ROYALTY PURCHASE AGREEMENT BETWEEN OMEROS CORPORATION AND DRI HEALTHCARE ACQUISITIONS LP Dated as of September 30, 2022 ? ? ? ? ? ? TABLE OF CONTENTS Page Article I DEFINITIONS; INTERPRETATION Section 1.1Definitions?1 Section 1.2Certain Interpretations?8 Article II PURCHASE AND SALE OF PURCHASED Assets Section 2.1Purchase and Sale of Purchased Assets?8 Section 2.2No Purchase or Sa

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): September 30, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (

Omeros Corporation Reports Second Quarter 2022 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports Second Quarter 2022 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? August 9, 2022 ? Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 9, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Comm

Current Report

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 17, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Omeros Corporation Reports First Quarter 2022 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports First Quarter 2022 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? May 10, 2022 ? Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation

ourteenth Amendment to Lease dated January 14, 2022 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.1 ? FOURTEENTH AMENDMENT TO LEASE THIS FOURTEENTH AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 14th day of January, 2022 (the ?Fourteenth Amendment Execution Date?), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (?Landlord?), and OMEROS CORPORATION, a Washington corporation (?Tenant?). RECITALS A.WHEREAS, Landlord and Tenant are part

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 10, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commis

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 tmb-20220617xdef14a.htm DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Asset Purchase Agreement, dated as of December 1, 2021 among Omeros Corporation, Rayner Surgical Inc. and Rayner Surgical Group, Limited, as Parent Guarantor

Exhibit 10.1 ? ? ? ASSET PURCHASE AGREEMENT ? By and Among ? OMEROS CORPORATION ? as Seller ? RAYNER SURGICAL INC. ? as Purchaser ? and ? solely for the purposes of Article V and Section 6.24 ? RAYNER SURGICAL GROUP LIMITED ? as Parent Guarantor ? Dated as of December 1, 2021 ? [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD

As filed with the Securities and Exchange Commission on March 1, 2022

POSASR 1 tm227675d1posasr.htm POSASR As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333-235349 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washington (State or

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Omeros Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 1, 2022 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commi

As filed with the Securities and Exchange Commission on March 1, 2022

As filed with the Securities and Exchange Commission on March 1, 2022 Registration No.

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? March 1, 2022 ? Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) [] Computershare Trust Company, National Association (Exact name of trustee as specified in its charter)

Filing Fee Table

EX-FILING FEES 6 tm227675d1ex-filingfees.htm EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Omeros Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Ra

Consent and Second Amendment to Loan and Security Agreement, dated as of December 1, 2021, by and between Omeros Corporation and Silicon Valley Bank

Exhibit 10.44 ? CONSENT AND SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT ? This Consent and Second Amendment to Loan and Security Agreement (this ?Amendment?) is entered into this 1st day of December, 2021, by and between SILICON VALLEY BANK (?Bank?) and OMEROS CORPORATION, a Washington corporation (?Borrower?) whose address is 201 Elliott Avenue West, Seattle, Washington 98119. RECITALS A.Bank

OMER / Omeros Corporation / Cormorant Asset Management, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Omeros Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

OMER / Omeros Corporation / Demopulos Gregory A MD Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 12)* OMEROS CORPORATION (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143 102 (CUSIP Number) December 31 , 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

OMER / Omeros Corporation / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Omeros Corp. Title of Class of Securities: Common Stock CUSIP Number: 682143102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 1

Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

Exhibit 99.1 Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical SEATTLE – December 23, 2021 - Omeros Corporation (Nasdaq: OMER) today announced that it has completed the sale of OMIDRIA (phenylephrine and ketorolac intraocular solution) 1.0%/0.3% to Rayner Surgical Group Inc., an affiliate of Rayner Surgical Group Limited. The transaction was completed pursuant to an Asset Purchase Agr

Omeros Corporation Unaudited Pro Forma Condensed Consolidated Financial Information

Exhibit 99.2 Omeros Corporation Unaudited Pro Forma Condensed Consolidated Financial Information On December 23, 2021, Omeros Corporation (?Omeros? or the ?Company?) closed on an Asset Purchase Agreement (the ?Asset Purchase Agreement?) with Rayner Surgical Inc. (the ?Purchaser?) and Rayner Surgical Group Limited, as parent guarantor, pursuant to which Omeros agreed to sell, and the Purchaser agre

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion -- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-

Exhibit 99.1 Omeros Announces Agreement to Sell OMIDRIA? Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion - Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 Inhibitors ? - Conference call today at 8:30 a.m. ET, 5:30 a.m. PT - ? $125 million upfront payment and $200 million on achievement of c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Omeros Corporation Reports Third Quarter 2021 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports Third Quarter 2021 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? November 9, 2021 ? Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflam

Master Service Agreement dated July 28, 2019, as amended, between Omeros Corporation and Lonza Biologics Tuas Pte Ltd.

Exhibit 10.1 ? ? MASTER SERVICES AGREEMENT AS AMENDED ? ? ? between ? ? ? LONZA BIOLOGICS TUAS PTE LTD ? ? ? and ? ? ? OMEROS CORPORATION ? ? [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED THIS AGREEMENT is made on the 28th day of July 2019 (the ?Effective Date?) and amended as

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): November 9, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Co

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 14, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Co

Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA -- Conference call today at 8:30 a.m. ET, 5:30 a.m. PT --

Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Conference call today at 8:30 a.

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): October 1, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Com

Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA

Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA SEATTLE ? October 1, 2021 - Omeros Corporation (Nasdaq: OMER) today announced that the U.

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): August 9, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Omeros Corporation Reports Second Quarter 2021 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports Second Quarter 2021 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? August 9, 2021 ? Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflamm

Thirteenth Amendment to Lease dated January 1, 2021 between Omeros Corporation and BMR-201 Elliott Avenue LLC

? THIRTEENTH AMENDMENT TO LEASE THIS THIRTEENTH AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 1st day of June, 2021 (the ?Thirteenth Amendment Execution Date?), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (?Landlord?), and OMEROS CORPORATION, a Washington corporation (?Tenant?).

Omeros Corporation 2017 Omnibus Incentive Compensation Plan (as amended and restated effective June 11, 2021)

? Exhibit 10.1 OMEROS CORPORATION 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 11, 2021) 1.Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility; ? to provide additional incentive to Employees, Directors and Consultants; and ? to promote the success of the Compa

As filed with the Securities and Exchange Commission on June 16, 2021

As filed with the Securities and Exchange Commission on June 16, 2021 Registration No.

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): June 11, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commi

Omeros Corporation 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 11, 2021).

Exhibit 4.3 OMEROS CORPORATION 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 11, 2021) 1. Purposes of the Plan. The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility; ? to provide additional incentive to Employees, Directors and Consultants; and ? to promote the success of the Company

OMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA -- PDUFA Date is October 17, 2021 –

OMEROS ANNOUNCES EXTENSION OF FDA REVIEW PERIOD FOR NARSOPLIMAB IN HSCT-TMA - PDUFA Date is October 17, 2021 ? SEATTLE ? May 20, 2021 - Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, immunologic diseases (e.

Financial Statements and Exhibits, Other Events

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 20, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commis

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): May 10, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commis

Quarterly Report - 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Omeros Corporation Reports First Quarter 2021 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 ? ? Omeros Corporation Reports First Quarter 2021 Financial Results ? ? Conference Call Today at 4:30 p.m. ET ? ? SEATTLE, WA ? May 10, 2021 ? Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammati

- DEF 14A

DEF 14A 1 tmb-20210611xdef14a.htm DEF 14A Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Twelfth Amendment to Lease dated January 1, 2021 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.24 TWELFTH AMENDMENT TO LEASE THIS TWELFTH AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 1st day of January, 2021 (the ?Twelfth Amendment Execution Date?), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (?Landlord?), and OMEROS CORPORATION, a Washington corporation (?Tenant?). RECITALS A.WHEREAS, Landlord and Tenant are parties to that

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.01 per share $150,000,000 $16,365.00

Use these links to rapidly review the document Table of Contents TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

the description of our common stock contained in Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021.

DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? Omeros Corporation may issue, separately or together with, or upon conversion, exercise or exchange of other securities, common stock, par value $0.

Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – March 1, 2021 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inf

Omeros Corporation Non-Employee Director Compensation Policy

? OMEROS CORPORATION NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Effective as of January 1, 2021) Omeros Corporation (the ?Company?) believes that the granting of equity and cash compensation to its Directors represents a powerful tool to attract, retain and reward Directors who are not Employees of the Company (?Outside Directors?) and to align the interests of our Outside Directors with those of our shareholders.

Annual Report - 10-K

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Sales Agreement, dated March 1, 2021, between Omeros Corporation and Cantor Fitzgerald & Co.

Exhibit 1.1 Omeros Corporation Shares of Common Stock (par value $0.01 per share) Controlled Equity OfferingSM Sales Agreement March 1, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 ? Ladies and Gentlemen: Omeros Corporation, a Washington corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1.Issuance and S

Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ? Date of Report (Date of earliest event reported): March 1, 2021 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) ? Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commi

Eleventh Amendment to Lease dated October 23, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC

Exhibit 10.23 ? ELEVENTH AMENDMENT TO LEASE THIS ELEVENTH AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 23rd day of October, 2020 (the ?Effective Date?), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (?Landlord?), and OMEROS CORPORATION, a Washington corporation (?Tenant?). RECITALS A.WHEREAS, Landlord and Tenant are parties to that certain Leas

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OMEROS CORP (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 6821

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OMEROS CORP (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Omeros Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OMEROS CORP (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 6821

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* OMEROS CORP (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 11)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* OMEROS CORPORATION (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143 102 (CUSIP Number) December 31 , 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Omeros Corp. Title of Class of Securities: Common Stock CUSIP Number: 682143102 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1

Omeros Corporation Reports Third Quarter 2020 Financial Results

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2020 Financial Results SEATTLE, WA – November 9, 2020 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

Tenth Amendment to Lease dated September 15, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC

TENTH AMENDMENT TO LEASE THIS TENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of September, 2020 (the “Tenth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Omeros Announces Pricing of Public Offerings --6,900,000 Shares of Common Stock-- --$210,000,000 of 5.25% Convertible Senior Notes due 2026--

Exhibit 99.1 Omeros Announces Pricing of Public Offerings -6,900,000 Shares of Common Stock- -$210,000,000 of 5.25% Convertible Senior Notes due 2026- SEATTLE-(BUSINESS WIRE)—August 12, 2020 - Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has priced concurrent underwritten public offerings of 6,900,000 of shares of its common stock (the “Shares”) at a public offering price o

Underwriting Agreement, dated as of August 11, 2020, between Omeros Corporation and BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the Equity Underwriters.

Exhibit 1.1 Execution Version OMEROS CORPORATION 6,900,000 Shares of Common Stock UNDERWRITING AGREEMENT August 11, 2020 BOFA SECURITIES, INC. J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Ladies and Gentlemen: 1. INTRODUCTORY. Omeros Corpora

Opinion of Covington & Burling LLP with respect to the Notes.

Exhibit 5.3 August 14, 2020 Omeros Corporation 201 Elliott Avenue West Seattle, Washington 98119 Ladies and Gentlemen: We have acted as special counsel to Omeros Corporation, a Washington corporation (the “Company”), in connection with the offering by the Company under the Securities Act of 1933 (the “Securities Act”) of up to $241,500,000 in aggregate principal amount (including up to $31,500,000

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fi

Form of capped call transaction confirmation, in reference to the 5.25% Convertible Senior Notes due 2026

Exhibit 10.1 []1 To: Omeros Corporation 201 Elliott Avenue West Seattle, WA 98119 From: [] Re: [Base]2[Additional]3 Capped Call Transaction Ref. No: []4 Date: [], 2020 Dear Ladies and Gentlemen: The purpose of this communication (this “Confirmation”) is to set forth the terms and conditions of the above-referenced transaction entered into on the Trade Date specified below (the “Transaction”) betwe

First Supplemental Indenture, dated as of August 14, 2020, between Omeros Corporation and Wells Fargo Bank, National Association, as trustee (including the form of 5.25% Convertible Senior Notes due 2026)

Exhibit 4.2 EXECUTION VERSION OMEROS CORPORATION and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of August 14, 2020 5.25% Convertible Senior Notes due 2026 CROSS REFERENCE TABLE* Trust Indenture Act Indenture Section Section 310 (a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311 (a) N/A (b) N/A (c) N/A 312 (a) 2.08 (b) N/A (c) N/A

Indenture, dated as of August 14, 2020, between Omeros Corporation and Wells Fargo Bank, National Association, as trustee

Exhibit 4.1 OMEROS CORPORATION and WELLS FARGO BANK, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of August 14, 2020 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions. 1 Section 1.2 Compliance Certificates and Opinions. 7 Section 1.3 Form of Documents Delivered to Trustee. 8 Section 1.4 Acts of Holders; R

Underwriting Agreement, dated as of August 11, 2020, between Omeros Corporation and BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the Notes Underwriters.

Exhibit 1.2 Execution Version OMEROS CORPORATION 5.25% Convertible Senior Notes due 2026 UNDERWRITING AGREEMENT August 11, 2020 BOFA SECURITIES, INC. J.P. MORGAN SECURITIES LLC As Representatives of the several Underwriters c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 Ladies and Gentlemen: 1. INTRODUCTORY. Omeros

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Proposed Maximum Offering Price Per Security Proposed Maximum Aggregate Offering Price Amount of Registration fee(2)(3) Common Stock, par value $0.01

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Amount of Registration Fee 5.25% Convertible Senior Notes due 2026 24

Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

PRICING TERM SHEET August 11, 2020 Omeros Corporation Offerings of 6,900,000 Shares of Common Stock $210,000,000 Aggregate Principal Amount of 5.25% Convertible Senior Notes due 2026

Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration File No. 333-235349 Relating to the Preliminary Prospectus Supplements Dated August 10, 2020 (To Prospectus Dated December 4, 2019) PRICING TERM SHEET August 11, 2020 Omeros Corporation Offerings of 6,900,000 Shares of Common Stock and $210,000,000 Aggregate Principal Amount of 5.25% Convertible Senior Notes due 2026 The inform

Omeros Corporation Reports Second Quarter 2020 Financial Results

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2020 Financial Results SEATTLE, WA – August 10, 2020 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of

Subject to completion, dated August 10, 2020

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission Fi

Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes

FWP 1 a20-112936fwp.htm FWP Filed pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement No. 333-235349 August 10, 2020 Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes SEATTLE—(BUSINESS WIRE)—August 10, 2020 — Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced that it has commenced concurrent underwritten public offerings of $12

First Amendment to Loan and Security Agreement, dated as of August 7, 2020, by and between Omeros Corporation and Silicon Valley Bank

FIRST Amendment to Loan and security agreement This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 7th day of August, 2020, by and between SILICON VALLEY BANK (“Bank”) and OMEROS CORPORATION, a Washington corporation (“Borrower”) whose address is 201 Elliott Avenue West, Seattle, Washington 98119.

Subject to completion, dated August 10, 2020

Use these links to rapidly review the document TABLE OF CONTENTS Prospectus Supplement TABLE OF CONTENTS Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Consulting Agreement, dated as of February 10, 2020, between Omeros Corporation and Kurt Zumwalt

OMEROS CORPORATION CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered into by and between Omeros Corporation (“Omeros”) and Kurt Zumwalt (the “Consultant”) as of February 10, 2020 1.

Omeros Corporation Reports First Quarter 2020 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports First Quarter 2020 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – May 11, 2020 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, comp

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Ninth Amendment to Lease dated January 15, 2020 between Omeros Corporation and BMR-201 Elliott Avenue LLC

NINTH AMENDMENT TO LEASE THIS NINTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of January, 2020 (the “Ninth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”).

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of May 4, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13D and/or

OMER / Omeros Corp. / Cormorant Asset Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Omeros Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 682143102 (CUSIP Number) April 24, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

- DEFA14A

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Definitive Proxy Statement on Schedule 14A for our 2020 Annual Meeting of Stockholders, filed with the SEC on April 29, 2020

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – March 2, 2020 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inf

Annual Report - 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

Eighth Amendment to Lease dated October 18, 2019 between Omeros Corporation and BMR-201 Elliott Avenue LLC

EIGHTH AMENDMENT TO LEASE THIS EIGHTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 18th day of October, 2019 (the “Eighth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”).

Description of Common Stock

DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANG ACT OF 1934 Omeros Corporation may issue, separately or together with, or upon conversion, exercise or exchange of other securities, common stock, par value $0.

OMER / Omeros Corp. / Demopulos Gregory A MD - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10) Omeros Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143 102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

OMER / Omeros Corp. / Consonance Capital Management LP - CONSONANCE CAPITAL MANAGEMENT LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 OMEROS CORP (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

OMER / Omeros Corp. / D. E. SHAW & CO, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1) Under the Securities Exchange Act of 1934 Omeros Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to which the Sched

JOINT FILING AGREEMENT

Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros --

Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors - Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros - SEATTLE, WA – February 11, 2020 – Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2020 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

LETTER

January 30, 2020 Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer Omeros Corp 201 Elliott Avenue West Seattle, Washington 98119 Re: Omeros Corp For 10-K for the Fiscal Year Ended December 31, 2018 Filed March 1, 2019 File No. 001-34475 Dear Mr. Jacobsen: We have completed our review of your filing. We remind you that the company and its management are responsible

OMER / Omeros Corp. TEXT-EXTRACT - -

January 30, 2020 Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer Omeros Corp 201 Elliott Avenue West Seattle, Washington 98119 Re: Omeros Corp For 10-K for the Fiscal Year Ended December 31, 2018 Filed March 1, 2019 File No. 001-34475 Dear Mr. Jacobsen: We have completed our review of your filing. We remind you that the company and its management are responsible

OMER / Omeros Corp. AW - - AW

AW 1 a20-18831aw.htm AW January 13, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Omeros Corporation Application for Withdrawal of Post-Effective Amendment No. 2 to Registration Statement on Form S-3 Filed March 1, 2019 File No. 333-219959 Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended

OMER / Omeros Corp. CORRESP - -

January 10, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attn: Sasha Parikh Re: Omeros Corporation Form 10-K for the Fiscal Year Ended December 31, 2018 Filed March 1, 2019 File No. 001-34475 Dear Ms. Parikh: On behalf of Omeros Corporation (the “Company”), I am responding to the comment of the staff of the Division of Corporati

OMER / Omeros Corp. TEXT-EXTRACT - -

December 30, 2019 Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer Omeros Corp 201 Elliott Avenue West Seattle, Washington 98119 Re: Omeros Corp For 10-K for the Fiscal Year Ended December 31, 2018 Filed March 1, 2019 File No. 001-34475 Dear Mr. Jacobsen: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us wit

LETTER

December 30, 2019 Michael A. Jacobsen Vice President, Finance, Chief Accounting Officer and Treasurer Omeros Corp 201 Elliott Avenue West Seattle, Washington 98119 Re: Omeros Corp For 10-K for the Fiscal Year Ended December 31, 2018 Filed March 1, 2019 File No. 001-34475 Dear Mr. Jacobsen: We have reviewed your filing and have the following comment. In our comment, we may ask you to provide us wit

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission F

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Amount to be Registered(1) Proposed Maximum Offering Price per Security Proposed Maximum Aggregate Offering Price Amount of Registration Fee(2) Common Stock, par value

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No.

Underwriting Agreement, dated December 5, 2019, between Omeros Corporation and Cantor Fitzgerald & Co.

Exhibit 1.1 Execution Version OMEROS CORPORATION 3,816,793 Shares of Common Stock UNDERWRITING AGREEMENT December 5, 2019 Cantor Fitzgerald & Co. As Representative of the several Underwriters c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 Dear Sirs: 1. Introductory. Omeros Corporation, a Washington corporation (the “Company”), proposes to sell, pursuant to the terms of this A

Omeros Announces Pricing of Upsized Public Offering of Common Stock

Exhibit 99.1 Omeros Announces Pricing of Upsized Public Offering of Common Stock SEATTLE—(BUSINESS WIRE)—December 5, 2019-Omeros Corporation (Nasdaq: OMER) (“Omeros”), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated

Power of Attorney***

S-3ASR 1 a2239506zs-3asr.htm S-3ASR Use these links to rapidly review the document TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 4, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMEROS CORPORATION (Exact name of registrant as specified in its ch

Subject to completion, dated December 4, 2019

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Master Services Agreement, dated July 28, 2019, between Omeros Corporation and Lonza Biologics Tuas Pte. Ltd.

Exhibit 10.1 MASTER SERVICES AGREEMENT between LONZA BIOLOGICS TUAS PTE LTD and OMEROS CORPORATION [***] CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (A) IS NOT MATERIAL AND (B) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED THIS AGREEMENT is made on the 28th day of July 2019 (the “Effective Date”) BETWEEN 1. LONZA BIOLOGICS TUAS PTE LTD, of 35 Tuas South

Omeros Corporation Reports Third Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Third Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – November 12, 2019 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001‑34475 91‑1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

Omeros Corporation Reports Second Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports Second Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – August 8, 2019 – Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, c

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001‑34475 91‑1663741 (State or Other Jurisdiction of Incorporation) (Commission Fil

Loan and Security Agreement, dated as of August 2, 2019, by and between Omeros Corporation and Silicon Valley Bank

Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of August 2, 2019 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and OMEROS CORPORATION, a Washington corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: 1 ACCOUNTING

Seventh Amendment to Lease dated April 15, 2019 between Omeros Corporation and BMR-201 Elliott Avenue LLC

EXHIBIT 10.1 SEVENTH AMENDMENT TO LEASE THIS SEVENTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 15th day of April, 2019 (the “Effective Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”). RECITALS A.  WHEREAS, Landlord and Tenant are parties to that certain Lease dat

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001‑34475 91‑1663741 (State or Other Jurisdiction of Incorporation) (Commission File

OMER / Omeros Corp. S-8 - - FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on June 11, 2019 Registration No.

2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 11, 2021)

Exhibit 10.1 OMEROS CORPORATION 2017 Omnibus Incentive Compensation Plan (as amended and restated effective as of June 7, 2019) 1.Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility; • to provide additional incentive to Employees, Directors and Consultants; and • to promote the success of the Company’

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

OMER / Omeros Corp. / D. E. SHAW & CO, L.P. - SC 13G Passive Investment

SC 13G 1 tv521293sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Omeros Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143102 (CUSIP Number) April 30, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursuant to wh

JOINT FILING AGREEMENT

Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 omer-8k20190501.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Inc

Omeros Corporation Reports First Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET –

Exhibit 99.1 Omeros Corporation Reports First Quarter 2019 Financial Results – Conference Call Today at 4:30 p.m. ET – SEATTLE, WA – May 9, 2019 – Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, compl

Quarterly Report - 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

OMER / Omeros Corp. DEF 14A DEF 14A

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

JOINT FILING AGREEMENT

Exhibit 2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, each of the undersigned Reporting Persons hereby agrees to the joint filing, along with all other such Reporting Persons, on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0.

POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940

Exhibit 1 POWER OF ATTORNEY FOR CERTAIN REGULATORY FILINGS INCLUDING CERTAIN FILINGS UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND THE INVESTMENT ADVISERS ACT OF 1940 I, David E.

OMER / Omeros Corp. / D. E. SHAW & CO, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 tv515823sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Omeros Corporation (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 682143102 (CUSIP Number) February 26, 2019 (Date of Event Which Requires Filing of this Statement) Check the following box to designate the rule pursu

OMER / Omeros Corp. POS AM

POS AM 1 d680289dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2019 Registration No. 333-219959 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMEROS CORPORATION (Exact name of registrant as specified in its charter) Washi

OMER / Omeros Corp. POST-EFFECTIVE AMENDMENT NO.1 TO FORM S-3

Post-Effective Amendment No.1 to Form S-3 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2019 Registration No. 333-219959 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMEROS CORPORATION (Exact name of registrant as specified in its charte

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2019 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission

Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results — Conference Call Today at 8:30 a.m. ET —

EX-99.1 Exhibit 99.1 Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results — Conference Call Today at 8:30 a.m. ET — SEATTLE, WA — March 1, 2019 — Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targe

Sixth Amendment to Lease dated October 18, 2018 between Omeros Corporation and BMR-201 Elliott Avenue LLC

SIXTH AMENDMENT TO LEASE THIS SIXTH AMENDMENT TO LEASE (this “Amendment”) is entered into as of this 18th day of October, 2018 (the “Sixth Amendment Execution Date”), by and between BMR-201 ELLIOTT AVENUE LLC, a Delaware limited liability company (“Landlord”), and OMEROS CORPORATION, a Washington corporation (“Tenant”).

our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the SEC on March 1, 2019;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-34475 OMEROS CORPORA